Derek A. Mann

Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Curative-intent treatments offer the best long-term outcomes for selected patients. However, recurrence rates after resection approach 70% at 5 years, and access to transplantation remains limited by donor scarcity and stringent eligibility criteria. Emerging data reveal that recurrence is a reflection of underlying tumour biology, immune evasion and microenvironmental permissiveness.

Brave Yellow Labrador's First Bark After Losing His Nose to Cancer Has People Sobbing Every pet parent's worst nightmare is when their furry friend is hurt or sick. Nothing is worse than when a dog gives you that look that says, "I …

Abstract Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is a leading cause of cancer-related mortality worldwide1,2. HCC occurs typically from a background of chronic liver disease, caused by a spectrum of predisposing conditions. Tumour development is driven by the expansion of clones that accumulate progressive driver mutations3, with hepatocytes the most likely cell of origin2.